AR056691A1 - Derivados pirrolopirimidina como inhibidores de syk - Google Patents

Derivados pirrolopirimidina como inhibidores de syk

Info

Publication number
AR056691A1
AR056691A1 ARP060104466A ARP060104466A AR056691A1 AR 056691 A1 AR056691 A1 AR 056691A1 AR P060104466 A ARP060104466 A AR P060104466A AR P060104466 A ARP060104466 A AR P060104466A AR 056691 A1 AR056691 A1 AR 056691A1
Authority
AR
Argentina
Prior art keywords
alkyl
3alkyl
cycloalkyl
halogen
formula
Prior art date
Application number
ARP060104466A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520838A external-priority patent/GB0520838D0/en
Priority claimed from GB0613485A external-priority patent/GB0613485D0/en
Priority claimed from GB0618237A external-priority patent/GB0618237D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR056691A1 publication Critical patent/AR056691A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Los derivados de pirrolopirimidina de formula (1) son inhibidores de Tirosina Quinasa Esplénica (Syk) y por lo tanto de potencial terapéuticamente beneficioso en el tratamiento de enfermedades y afecciones asociadas con la actividad inapropiada de Syk, en particular en el tratamiento de enfermedades inflamatorias y alérgica. Reivindicacion 1: Un compuesto de formula (1) o una sal o solvato del mismo donde: R1 es H o alquilo C1-3; R2 es alquilo C1-6, haloalquilo C1-6, donde cada cicloalquilo puede estar sustituido con uno o más sustituyentes seleccionados independientemente entre alquilo C1-3 o halogeno; R3 es un grupo de formula (2) en el que cada uno de R y T es H, y S es CONR8R9; R8 y R9 son independientemente H, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, cicloalquilo C3-7, alquilen C1-3-cicloalquilo C3-7, fenilo (opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halogeno, -alquilo C1-3, CN o SO2CF3), alquilen C1-3- fenilo, alquilen C1-3-O-alquilo C1-3; o R8 y R9; junto con el N al que están unidos forman un grupo heterocíclico de 4, 5 o 6 miembros, que contiene opcionalmente un heteroátomo adicional seleccionado entre O, S o N y opcionalmente sustituido sobre cada C hasta con dos alquilo C1-6 o halogeno, o con =O o alcoxi C1-6, sobre cualquier N opcional con alquilo C1-6, CO-alquilo C1-3 o COO-alquilo C1-6 y sobre cualquier S opcional con =O, o (=O)2; y R4 es H o -alquilo C1-3.
ARP060104466A 2005-10-13 2006-10-11 Derivados pirrolopirimidina como inhibidores de syk AR056691A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0520838A GB0520838D0 (en) 2005-10-13 2005-10-13 Novel compounds
GB0613485A GB0613485D0 (en) 2006-07-06 2006-07-06 Novel compounds
GB0618237A GB0618237D0 (en) 2006-09-15 2006-09-15 Novel compounds

Publications (1)

Publication Number Publication Date
AR056691A1 true AR056691A1 (es) 2007-10-17

Family

ID=37501750

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104466A AR056691A1 (es) 2005-10-13 2006-10-11 Derivados pirrolopirimidina como inhibidores de syk

Country Status (16)

Country Link
US (1) US20080004295A1 (es)
EP (2) EP1948658A1 (es)
JP (2) JP2009511528A (es)
KR (1) KR20080063837A (es)
AR (1) AR056691A1 (es)
AU (1) AU2006301435A1 (es)
BR (1) BRPI0617241A2 (es)
CA (1) CA2625109A1 (es)
CR (1) CR9929A (es)
EA (1) EA200800664A1 (es)
IL (1) IL190077A0 (es)
MA (1) MA29797B1 (es)
NO (1) NO20081349L (es)
PE (1) PE20070593A1 (es)
TW (1) TW200800215A (es)
WO (2) WO2007042299A1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
ATE523499T1 (de) 2006-07-06 2011-09-15 Array Biopharma Inc Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
CA2656364C (en) 2006-07-06 2014-11-25 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
TWI450720B (zh) 2007-07-05 2014-09-01 Array Biopharma Inc 作為ａｋｔ蛋白質激酶抑制劑之嘧啶環戊烷
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2401685T3 (es) 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
EA017952B1 (ru) 2008-02-06 2013-04-30 Новартис Аг ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
BRPI0921317A2 (pt) 2008-11-06 2017-06-06 Astrazeneca Ab composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
WO2010142027A1 (en) * 2009-06-12 2010-12-16 Socpra - Sciences Et Genie S. E. C. Guanine riboswitch binding compounds and their use as antibiotics
CA2765534C (en) 2009-06-15 2018-09-18 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
US8629132B2 (en) * 2009-11-13 2014-01-14 Genosco Kinase inhibitors
SI2516434T1 (sl) * 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
CN103874689B (zh) 2011-04-01 2016-04-27 基因泰克公司 Akt抑制剂化合物和威罗菲尼的组合及使用方法
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
KR20140028062A (ko) 2011-05-10 2014-03-07 머크 샤프 앤드 돔 코포레이션 Syk 억제제로서의 아미노피리미딘
EP2707357B1 (en) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
KR20140097127A (ko) * 2011-09-16 2014-08-06 포비어 파마수티칼스 아닐린 유도체, 그의 제조법 및 그의 치료 용도
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
BR112014012396B1 (pt) 2011-11-23 2020-08-25 Portola Pharmaceuticals, Inc inibidores de pirazina quinase, composição, método in vitro para inibição de quinase syk ou via de transdução de sinal, uso dos referidos inibidores e kit
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
EP2802568A1 (en) 2012-01-13 2014-11-19 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents.
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
WO2014093191A1 (en) 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014176216A1 (en) * 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
JP6564771B2 (ja) 2013-07-11 2019-08-21 エイシア バイオサイエンシーズ インコーポレイテッド キナーゼ阻害剤としてのピリミジン誘導体
CN105940000B (zh) 2013-10-21 2019-12-24 盖诺斯克公司 取代的嘧啶化合物及其作为syk抑制剂的用途
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
CN105940004B (zh) 2014-01-29 2018-02-02 葛兰素史密斯克莱知识产权发展有限公司 化合物
ES2717757T3 (es) * 2014-01-29 2019-06-25 Glaxosmithkline Ip Dev Ltd Compuestos
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
NO2721710T3 (es) 2014-08-21 2018-03-31
EP3778605A3 (en) * 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
CN107949388B (zh) 2015-10-09 2021-10-26 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
EP3558997B1 (en) 2016-12-20 2021-01-27 AstraZeneca AB Amino-triazolopyridine compounds and their use in treating cancer
US11208412B2 (en) 2017-02-22 2021-12-28 Daegu-Gyeongbuk Medical Innovation Foundation Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease
CN111212837A (zh) 2017-04-07 2020-05-29 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
WO2019133629A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase

Also Published As

Publication number Publication date
JP2009511527A (ja) 2009-03-19
WO2007042298A1 (en) 2007-04-19
EP1948659A1 (en) 2008-07-30
KR20080063837A (ko) 2008-07-07
WO2007042299A1 (en) 2007-04-19
US20080004295A1 (en) 2008-01-03
MA29797B1 (fr) 2008-09-01
BRPI0617241A2 (pt) 2016-11-08
TW200800215A (en) 2008-01-01
EP1948658A1 (en) 2008-07-30
JP2009511528A (ja) 2009-03-19
EA200800664A1 (ru) 2009-02-27
CR9929A (es) 2008-07-29
IL190077A0 (en) 2008-08-07
CA2625109A1 (en) 2007-04-19
AU2006301435A1 (en) 2007-04-19
NO20081349L (no) 2008-05-07
PE20070593A1 (es) 2007-07-23

Similar Documents

Publication Publication Date Title
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
AR068075A1 (es) Compuestos de piperazina con accion herbicida. proceso de preparacion
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20051142A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion para los mismos
AR053569A1 (es) Derivados de pirazol
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
AR068074A1 (es) Compuestos de piperazina con accion herbicida. proceso de preparacion
AR078944A1 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
ECSP109953A (es) Derivados de piridazinona
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR073932A1 (es) Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PE20090770A1 (es) Derivados de benzoxazolona

Legal Events

Date Code Title Description
FB Suspension of granting procedure